Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Measles epidemic and Salmonella outbreak cost nearly six million euros The most recent measles epidemic and outbreak of Salmonella Thomson due to smoked salmon have cost 3.9 and 1.7 million euros, respectively.
European Antibiotic Awareness Day: the fight against antibiotics resistance Wednesday, 18 November is European Antibiotic Awareness Day. On this day, attention throughout Europe is requested for the responsible use of antibiotics in people and animals.
CAESAR annual report 2014 The World Health Organization (WHO) published its first CAESAR annual report 2014.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
Antibiotic resistance is stable, however, more resistant bacteria are expected Over recent years, antibiotic resistance to most agents has remained stable in the Netherlands, and the use of antibiotics has slightly decreased.
RIVM seeks dialogue with Industry for safe and green chemistry RIVM would like to explore possibilities to eliminate obstacles during innovation of green chemistry with industry.